Home » Stocks » OMER

Omeros Corporation (OMER)

Stock Price: $17.75 USD 0.19 (1.08%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.12B
Revenue (ttm) 73.81M
Net Income (ttm) -138.06M
Shares Out 57.18M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $17.75
Previous Close $17.56
Change ($) 0.19
Change (%) 1.08%
Day's Open 17.49
Day's Range 17.49 - 18.05
Day's Volume 392,587
52-Week Range 9.25 - 23.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) di...

4 days ago - Business Wire

SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began...

1 month ago - Business Wire

Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 3.45% over the past year to ($0.60), which beat the esti...

2 months ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

2 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Mond...

2 months ago - Business Wire

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial...

3 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associate...

3 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare ...

3 months ago - Business Wire

Omeros: A Ripening Fruit Ready To Pick

4 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Om...

5 months ago - Business Wire

Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FD...

5 months ago - Business Wire

Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Omeros (OMER) delivered earnings and revenue surprises of 33.33% and 39.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

5 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9...

6 months ago - Business Wire

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual e...

6 months ago - Business Wire

The Omeros narsoplimab ship is finally coming in after long voyages in treacherous waters. Omeros' liquidity is improved but will likely remain challenging.

6 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy ...

6 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company's lead human monoc...

6 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated t...

6 months ago - Business Wire

OMER share price has been depressed over continued uncertainty regarding sales of their primary revenue-driver.

6 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular soluti...

7 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D.

7 months ago - Business Wire

Omeros (OMER) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. T...

8 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administr...

8 months ago - Business Wire

Omeros' COVID-19 Opportunity And Challenges

8 months ago - Seeking Alpha

The biopharma announced the pricing of a public offering of common stock and debt offering.

8 months ago - The Motley Fool

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock (the “Shares...

8 months ago - Business Wire

Omeros stock shot up more than 60% after the Seattle-based biotech company reported promising results from its COVID-19 drug treatment.

8 months ago - GeekWire

Omeros (OMER) delivered earnings and revenue surprises of 11.11% and -25.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has commenced concurrent underwritten public offerings of $125,000,000 of shares of its common stock (the “...

8 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

8 months ago - Business Wire

Omeros Corporation (NASDAQ: OMER) shares were galloping higher Monday after the biopharma announced results from a compassionate use study of its lead investigational human monoclonal antibody.

8 months ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting ma...

8 months ago - Business Wire

Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?

9 months ago - The Motley Fool

Today, we revisit Omeros. The company has two potential catalysts on the near term horizon and the stock is a good covered call candidate.

9 months ago - Seeking Alpha

Omeros shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75 appeared first on Inves...

11 months ago - Investors Business Daily

Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

Omeros Corporation: The Thesis Was Playing Out Before COVID-19 Hit

1 year ago - Seeking Alpha

Omeros closed out Q4 2019 with an excellent earnings report.

1 year ago - Seeking Alpha

The company reported full-year 2019 operating results and a separate update from the pipeline.

1 year ago - The Motley Fool

Omeros Corporation (OMER) CEO Greg Demopulos on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HS... [Read more...]

Industry
Biotechnology
IPO Date
Oct 8, 2009
CEO
Gregory Demopulos
Employees
277
Stock Exchange
NASDAQ
Ticker Symbol
OMER
Full Company Profile

Financial Performance

In 2020, Omeros's revenue was $73.81 million, a decrease of -33.98% compared to the previous year's $111.81 million. Losses were -$138.06 million, 63.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Omeros stock is "Buy." The 12-month stock price forecast is 27.00, which is an increase of 52.11% from the latest price.

Price Target
$27.00
(52.11% upside)
Analyst Consensus: Buy